临床心身疾病杂志
臨床心身疾病雜誌
림상심신질병잡지
JOURNAL OF CLINICAL PSYCHOSOMATIC DISEASES
2015年
4期
55-57
,共3页
难治性抑郁症%度洛西汀%喹硫平%联合用药%汉密顿抑郁量表%副反应量表
難治性抑鬱癥%度洛西汀%喹硫平%聯閤用藥%漢密頓抑鬱量錶%副反應量錶
난치성억욱증%도락서정%규류평%연합용약%한밀돈억욱량표%부반응량표
TRD%duloxetine%quetiapine%drug combination%HAMD%TESS
目的:探讨度洛西汀联合喹硫平治疗难治性抑郁症的临床疗效和安全性。方法将80例难治性抑郁症患者随机分为两组,每组40例,研究组口服度洛西汀联合喹硫平治疗,对照组口服度洛西汀治疗,观察8周。采用汉密顿抑郁量表评定临床疗效,副反应量表评定不良反应。结果研究组治疗1周末起,对照组治疗2周末起,汉密顿抑郁量表评分较治疗前显著下降(P<0.01),研究组治疗各时点评分显著低于对照组(P<0.05或0.01);治疗8周末研究组显效率79.5%、有效率92.3%,对照组分别为50.0%、60.5%,研究组显效率、有效率显著高于对照组(χ2=7.35、7.33,P<0.01)。两组不良反应均较轻微,发生率比较差异无显著性( P>0.05)。结论度洛西汀联合喹硫平治疗难治性抑郁症具有增效作用,起效快,疗效显著,安全性高,依从性好,优于单用度洛西汀治疗。
目的:探討度洛西汀聯閤喹硫平治療難治性抑鬱癥的臨床療效和安全性。方法將80例難治性抑鬱癥患者隨機分為兩組,每組40例,研究組口服度洛西汀聯閤喹硫平治療,對照組口服度洛西汀治療,觀察8週。採用漢密頓抑鬱量錶評定臨床療效,副反應量錶評定不良反應。結果研究組治療1週末起,對照組治療2週末起,漢密頓抑鬱量錶評分較治療前顯著下降(P<0.01),研究組治療各時點評分顯著低于對照組(P<0.05或0.01);治療8週末研究組顯效率79.5%、有效率92.3%,對照組分彆為50.0%、60.5%,研究組顯效率、有效率顯著高于對照組(χ2=7.35、7.33,P<0.01)。兩組不良反應均較輕微,髮生率比較差異無顯著性( P>0.05)。結論度洛西汀聯閤喹硫平治療難治性抑鬱癥具有增效作用,起效快,療效顯著,安全性高,依從性好,優于單用度洛西汀治療。
목적:탐토도락서정연합규류평치료난치성억욱증적림상료효화안전성。방법장80례난치성억욱증환자수궤분위량조,매조40례,연구조구복도락서정연합규류평치료,대조조구복도락서정치료,관찰8주。채용한밀돈억욱량표평정림상료효,부반응량표평정불량반응。결과연구조치료1주말기,대조조치료2주말기,한밀돈억욱량표평분교치료전현저하강(P<0.01),연구조치료각시점평분현저저우대조조(P<0.05혹0.01);치료8주말연구조현효솔79.5%、유효솔92.3%,대조조분별위50.0%、60.5%,연구조현효솔、유효솔현저고우대조조(χ2=7.35、7.33,P<0.01)。량조불량반응균교경미,발생솔비교차이무현저성( P>0.05)。결론도락서정연합규류평치료난치성억욱증구유증효작용,기효쾌,료효현저,안전성고,의종성호,우우단용도락서정치료。
Objective To explore the efficacy and safety of duloxetine plus quetiapine in treatment‐resist‐ant depression (TRD) .Methods Eighty TRD patients were randomly divided into two groups of 40 ones each ,research group took orally duloxetine plus quetiapine and control group did duloxetine for 8 weeks . Efficacies were assessed using the Hamilton Depression Scale (HAMD) and adverse reactions with the Treatment Emergent Symptom Scale (TESS) .Results The HAMD score lowered more significantly since the end of the 1st week in research group and since the 2nd in control compared with pretreatment (P<0 .01) ,so did that at each time‐point in research than in control group (P<0 .05 or 0 .01);at the end of the 8th week obvious effective and effective rate were respectively 79 .55% and 92 .3% in research and 50 .0% and 60 .5% in control group ,the former were significantly than the latter (χ2 =7 .35 ,7 .33;P<0 .01) .Adverse reactions of both groups were mild ,there were no significant group difference in the inci‐dence of adverse reactions .Conclusion Duloxetine plus quetiapine has a synergism ,takes effect more rapidly ,and has an evident effect ,higher safety and better compliance compared with single duloxetine in the treatment of treatment‐resistant depression .